Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an… Read more
Matinas BioPharma Holdings Inc (MTNB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.228x
Based on the latest financial reports, Matinas BioPharma Holdings Inc (MTNB) has a cash flow conversion efficiency ratio of -0.228x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.47 Million) by net assets ($6.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Matinas BioPharma Holdings Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Matinas BioPharma Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Matinas BioPharma Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Matinas BioPharma Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gromutual Bhd
KLSE:9962
|
-0.015x |
|
Bioalpha Holdings Bhd
KLSE:0179
|
-0.073x |
|
Universal Ibogaine Inc
PINK:IBOGF
|
-0.405x |
|
RFG Holdings Ltd
JSE:RFG
|
0.121x |
|
Sonim Technologies Inc
NASDAQ:SONM
|
10.034x |
|
Tego Cyber Inc
PINK:TGCB
|
0.070x |
|
Kiplin Metals Inc
PINK:ALDVF
|
-0.015x |
|
SRJ Technologies Group Plc
AU:SRJ
|
-0.052x |
Annual Cash Flow Conversion Efficiency for Matinas BioPharma Holdings Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Matinas BioPharma Holdings Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.59 Million | $-15.88 Million | -2.093x | -163.64% |
| 2023-12-31 | $19.25 Million | $-15.28 Million | -0.794x | -51.82% |
| 2022-12-31 | $36.64 Million | $-19.16 Million | -0.523x | -80.29% |
| 2021-12-31 | $52.49 Million | $-15.22 Million | -0.290x | -6.42% |
| 2020-12-31 | $63.73 Million | $-17.37 Million | -0.273x | +36.08% |
| 2019-12-31 | $33.05 Million | $-14.09 Million | -0.426x | +33.32% |
| 2018-12-31 | $16.14 Million | $-10.32 Million | -0.639x | +40.40% |
| 2017-12-31 | $10.68 Million | $-11.46 Million | -1.073x | -25.36% |
| 2016-12-31 | $7.15 Million | $-6.12 Million | -0.856x | +33.50% |
| 2015-12-31 | $6.07 Million | $-7.81 Million | -1.287x | +63.99% |
| 2014-12-31 | $2.23 Million | $-7.96 Million | -3.573x | -1152.77% |
| 2013-12-31 | $10.47 Million | $-2.99 Million | -0.285x | -69.33% |
| 2012-12-31 | $339.94K | $-57.26K | -0.168x | -- |